Latest News

FDA grants de novo clearance to Stone Clear device
FDA grants de novo clearance to Stone Clear device

November 13th 2024

"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1
FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

September 4th 2024

Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse
Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse

August 29th 2024

Increasing thiazide doses linked to fewer kidney stone events
Increasing thiazide doses linked to fewer kidney stone events

August 27th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1
Trial launches of gene editing therapy for primary hyperoxaluria type 1

August 24th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.